• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Lateral switch vs. escalation: 2 reports

October 5, 2013  

Identifying SPMS in practice

October 4, 2013  

MS therapies: analyses and re-analyses of phase III studies

October 4, 2013  

Dietary sodium linked to increased disease activity in MS

October 4, 2013  

MRI measures provide reliable indication of treatment response

October 3, 2013  

Better prognosis for OCB-negative patients

October 3, 2013  

Vitamin D a useful add-on treatment in MS

October 3, 2013  

Optimizing treatment of RRMS: Canadian recommendations

September 4, 2013  

Who prescribes DMTs for MS?

June 5, 2013  

Alemtuzumab: phase III results

April 10, 2013  
Previous
33
34
35
36
37
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions